Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24564714 | 1.00 | ALDH1A1 (0.45) | ALDH1A1ALOX15MAPK1LMNAMAPT | |
| SCHEMBL24564698 | 1.00 | ALDH1A1 (0.45) | ALDH1A1ALOX15MAPK1LMNAMAPT | |
| SCHEMBL24564689 | 1.00 | ALDH1A1 (0.45) | ALDH1A1ALOX15MAPK1LMNAMAPT | |
| SCHEMBL29697162 | 1.00 | ALDH1A1 (0.45) | ALDH1A1ALOX15MAPK1LMNAMAPT | |
| SCHEMBL24564690 | 1.00 | ALDH1A1 (0.45) | ALDH1A1ALOX15MAPK1LMNAMAPT | |
| SCHEMBL24564561 | 1.00 | ALDH1A1 (0.45) | ALDH1A1ALOX15MAPK1LMNAMAPT | |
| SCHEMBL24581234 | 0.91 | LMNA (0.42) | ALDH1A1LMNAMAPTL3MBTL1HRH3 | |
| SCHEMBL24581205 | 0.91 | LMNA (0.42) | ALDH1A1LMNAMAPTL3MBTL1HRH3 | |
| SCHEMBL23957498 | 0.83 | MAPT (0.48) | ALDH1A1LMNAMAPTL3MBTL1KMT2A | |
| SCHEMBL24564713 | 0.82 | ALDH1A1 (0.47) | ALDH1A1ALOX15MAPK1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022140464-A1 | COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220204471-A1 | Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204471-A1 | Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2 | HLA-DRB1, CD74, HLA-B | ALDH1A1 3804/4885ALOX15 1452/4885MAPK1 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.